Targeting the unstable plaque in acute coronary syndromes

Clinical Therapeutics

Volumn 35, Issue 8, 2013, Pages 1099-1107

  Thompson, Peter L ^a   Nidorf, S Mark ^b   Eikelboom, John ^c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Heart Care Western Australia   (Australia)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Acute coronary syndromes; Atherosclerosis; Canakinumab; Colchicines; Darapladib; Methotrexate; Plaque instability

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB; CD40 LIGAND; CHOLESTEROL; COLCHICINE; DARAPLADIB; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; LIPID; LOW DENSITY LIPOPROTEIN; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE CORONARY SYNDROME; ATHEROSCLEROTIC PLAQUE; CORONARY ARTERY DISEASE; CRYSTALLIZATION; HUMAN; MEDLINE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; SIGNAL TRANSDUCTION; STENT;

ACUTE CORONARY SYNDROMES; ATHEROSCLEROSIS; CANAKINUMAB; COLCHICINES; DARAPLADIB; METHOTREXATE; PLAQUE INSTABILITY;

ACUTE CORONARY SYNDROME; ANIMALS; ANTI-INFLAMMATORY AGENTS; CHOLESTEROL; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PERCUTANEOUS CORONARY INTERVENTION; PHOSPHOLIPASE A2 INHIBITORS; PLAQUE, ATHEROSCLEROTIC;

EID: 84882986868     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.07.332     Document Type: Review

References (76)

1. Davies M.J., Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 1984, 310:1137-1140.
2. Gorlin R., Fuster V., Ambrose I.A. Anatomic-physiologic links between acute coronary syndromes. Circulation 1986, 74:6J-9J.
3. Davies M.J. Stability and instability: two faces of coronary atherosclerosis. Circulation 1996, 94:2013-2020.
4. Fuster V., Moreno P.R., Fayad Z.A., Corti R., Badimon J.J. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol 2005, 46:937-954.
5. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999, 340:115-125.
6. Rathore S., Terashima M., Matsuo H., et al. Association of coronary plaque composition and arterial remodelling: a optical coherence tomography study. Atherosclerosis 2012, 221:405-415.
7. Narula J., Nakano M., Virmani R., et al. Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques. J Am Coll Cardiol 2013, 61:1041-1051.
8. Bennett M.R. Apoptosis of vascular smooth muscle cells in vascular remodelling and atherosclerotic plaque rupture. Cardiovasc Res 1999, 41:361-368.
9. Galis Z.S., Sukhova G.K., Lark M.W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994, 94:2493-2503.
10. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
11. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
12. Calabrò P., Yeh E.T. The pleiotropic effects of statins. Curr Opin Cardiol 2005, 20:541-546.
13. Vita J.A., Yeung A.C., Winniford M., et al. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation 2000, 102:846-851.
14. Dupuis J., Tardif J.C., Cernacek P., Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999, 99:3227-3233.
15. Briel M., Schwartz G.G., Thompson P.L., et al. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA 2006, 295:2046-2056.
16. Cannon C.P., Braunwald E., McCabe C., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction Investigators. N Engl J Med 2004, 350:1495-1504.
17. Reddy G., Bittner V. LDL lowering after acute coronary syndrome: is lower better?. Curr Treat Options Cardiovasc Med 2013, 15:33-40.
18. Tall A.R., Yvan-Charvet L., Wang N. The failure of torcetrapib: was it the molecule or the mechanism?. Arterioscler Thromb Vasc Biol 2007, 27:257-260.
19. Schwartz G.G., Olsson A.G., Abt M., et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012, 367:2089-2099.
20. Singh I.M., Shishehbor M.H., Ansell B.J. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 2007, 298:786-798.
21. Nissen S.E., Tsunoda T., Tuzcu E.M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290:2292-2300.
22. ETC-216 phospholipid. Drug developmenttechnology.com. Accessed May 10, 2013. http://www.drugdevelopment-technology.com/projects/etc/.
23. Tardif J.C., Gregoire J., L'Allier P.L., et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007, 297:1675-1682.
24. Waksman R., Torguson R., Kent K.M., et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol 2010, 55:2727-2735.
25. deGoma E.M., Rader D.J. Novel HDL-directed pharmacotherapeutic strategies. Nat Rev Cardiol 2011, 8:266-277.
26. Tardif J.C. Emerging high-density lipoprotein infusion therapies: fulfilling the promise of epidemiology?. J Clin Lipidol 2010, 4:399-404.
27. Serruys P.W., García-García H.M., Buszman P., et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008, 118:1172-1182.
28. Mohler E.R., Ballantyne C.M., Davidson M.H., et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2008, 51:1632-1641.
29. Siefert S.A., Sarkar R. Matrix metalloproteinases in vascular physiology and disease. Vascular 2012, 20:210-216.
30. Lee R.T., Schoen F.J., Loree H.M., et al. Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis: implications for plaque rupture. Arterioscler Thromb Vasc Biol 1996, 16:1070-1073.
31. MacFadyen R.J. Can matrix metalloproteinase inhibitors provide a realistic therapy in cardiovascular medicine?. Curr Opin Pharmacol 2007, 7:171-178.
32. Rabbini R., Topol E.J. Strategies to achieve coronary arterial plaque stabilization. Cardiovasc Res 1999, 41:402-412.
33. Kaptoge S., Di Angelantonio E., Pennells L., et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012, 367:1310-1320.
34. Grad E., Danenberg H.D. C-reactive protein and atherothrombosis: cause or effect?. Blood Rev 2013, 27(1):23-29.
35. Pepys M.B. CRP or not CRP? That is the question. Arterioscler Thromb Vasc Biol 2005, 25:1091.
36. Bogaty P., Brophy J.M., Noel M., et al. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study. Circulation 2004, 110:934-939.
37. Baron J.A., Sandler R.S., Bresalier R.S., et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 2008, 372:1756-1764.
38. Pepys M.B. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006, 440:1217-1221.
39. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002, 46:328-346. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines.
40. Javed Q., Murtaza I. Therapeutic potential of tumour necrosis factor-alpha antagonists in patients with chronic heart failure. Heart Lung Circ 2013, 22:323-327.
41. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285.
42. Lopez-Olivo M.A., Tayar J.H., Martinez-Lopez J.A., et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 2012, 308:898-908.
43. Park H.J., Ranganathan P. TNF-alpha antagonism and cancer risk in rheumatoid arthritis: is continued vigilance warranted?. Discov Med 2012, 13:229-234.
44. Ljung L., Simard J.F., Jacobsson L., Rantapää-Dahlqvist S., Askling J. Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis. Arthritis Rheum 2012, 64:42-52.
45. Maier W., Altwegg L.A., Corti R., et al. Inflammatory markers at the site of ruptured plaque in acute myocardial infarction. Circulation 2005, 11:1355-1361.
46. Sarwar, Butterworth A.S., Freitag DF, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012, 379:1205-1213. IL6R Genetics Consortium Emerging Risk Factors Collaboration.
47. Mihara M., Nishimoto N., Ohsugi Y. The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin Biol Ther 2005, 5:683-690.
48. Ito H. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004, 126:989-996.
49. Crossman D.C., Morton A.C., Gunn J.P., et al. Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study). Trials 2008, 9:8.
50. Latz E. The inflammasomes: mechanisms of activation and function. Curr Opin Immunol 2010, 22:28-33.
51. Pamukcu B., Lip G.Y., Snezhitskiy V., Shantsila E. The CD40-CD40L system incardiovascular disease. Ann Med 2011, 43:331-340.
52. Antoniades C., Bakogiannis C., Tousoulis D., Antonopoulos A.S., Stefanadis C. TheCD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 2009, 54:669-677.
53. De Winther M.P., Kanters E., Kraal G., Hofker M.H. Nuclear factor kappaB signaling in atherogenesis. Arterioscler Thromb Vasc Biol 2005, 25:904-914.
54. Pamukcu B., Lip G.Y., Shantsila E. The nuclear factor-kappa B pathway in atherosclerosis: a potential therapeutic target for atherothrombotic vascular disease. Thromb Res 2011, 128:117-123.
55. Fraser C.C. Exploring the positive and negative consequences of NF-kappaB inhibition for the treatment of human disease. Cell Cycle 2006, 5:1160-1163.
56. Nam N.H. Naturally occurring NF-kappaB inhibitors. Mini Rev Med Chem 2006, 6:945-951.
57. Capini C., Jaturanpinyo M., Chang H.I., et al. Antigen-specific suppression of inflammatory arthritis using liposomes. J Immunol 2009, 182:3556-3565.
58. Classics in arteriosclerosis research: on experimental cholesterin steatosis and its significance in the origin of some pathological processes by N. Anitschkow and S. Chalatow, translated by Mary Z. Pelias, 1913. Arteriosclerosis. 1983;3:178-182.
59. Rajamäki K., Lappalainen J., Oörni K., et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 2010, 5:e11765.
60. Duewell P., Kono H., Rayner K.J., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464:1357-1361.
61. Grebe A., Latz E. Cholesterol crystals and inflammation. Curr Rheumatol Rep 2013, 15:313.
62. Abela G.S., Aziz K. Cholesterol crystals rupture biological membranes and human plaques during acute cardiovascular events-a novel insight into plaque rupture by scanning electron microscopy. Scanning 2006, 28:1-10.
63. Abela G.S. Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation. J Clin Lipidol 2010, 4:156-164.
64. Waxman S., Ishibashi F., Muller J.E. Detection and treatment of vulnerable plaques and vulnerable patients: novel approaches to prevention of coronary events. Circulation 2006, 114:2390-2411.
65. Smits P.C., Hofma S., Togni M., et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. Lancet 2013, 381:651-660.
66. White H., Held C., Stewart R., et al. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. Am Heart J 2010, 160:655-661.
67. O'Donoghue M.L., Braunwald E., White H.D., et al. Study design and rationale for the Stabilization of pLaques using Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. Am Heart J 2011, 162:613-619.
68. Micha R., Imamura F., Wyler von Ballmoos M., et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011, 108:1362-1370.
69. Landewé R.B.M., van den Borne B.E.E., Breedveld F.C. Dijkmans BAC. Methotrexate effects in patients with rheumatoid arthritis with cardiovascular co-morbidity. Lancet 2000, 355:616-617.
70. Visser K., van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 2009, 68:1094-1099.
71. Salliot C., van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009, 68:1100-1104.
72. Ridker P.M. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost 2009, 7(Suppl 1):332-339.
73. Lowry F. FDA Panel says no to canakinumab for gout attacks. Accessed May 10, 2013. http://www.medscape.com/viewarticle/745076.
74. Ridker P.M., Thuren T., Zalewski A., Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011, 162:597-605.
75. Nidorf M., Thompson P.L. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am J Cardiol 2007, 99:805-807.
76. Nidorf S.M., Eikelboom J.W., Budgeon C.A., Thompson P.L. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013, 61:404-410.